Ztalmy

Chemical Nameganaxolone
Dosage FormSuspension (oral; 50 mg/mL)
Drug ClassModulators
SystemNervous
CompanyMarinus Pharmaceuticals
Approval Year2022

Indication

  • For the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older
Last updated on 4/27/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ztalmy (ganaxolone) Prescribing Information. 2022Marinus Pharmaceuticals, Inc., Radnor, PA